A molecular system controlled by a protein called FBP1 is responsible for how liver cells damaged by MASH — fully,…
Articles by Marisa Wexler, MS
Alagille syndrome may cause problems with skull development that can put abnormal pressure on the brain, and screening babies…
Tobevibart and elebsiran, an experimental treatment combination that Vir Biotechnology is developing for chronic hepatitis D, has been…
A branch of the European Medicines Agency (EMA) has recommended that Gilead Sciences’ oral therapy seladelpar be approved in…
Cholestasis is a common complication among critically ill people with COVID 19-associated acute respiratory distress syndrome (ARDS), a life-threatening…
Kidney and blood vessel problems are common in people with Alagille syndrome, and while these often cause few to…
After 2.5 years of Livdelzi (seladelpar) treatment, more than 4 in 5 adults with primary biliary cholangitis (PBC)…
Nearly 1.5 years of treatment with Bylvay (odevixibat) effectively reduces itching and liver damage markers, and improves growth and…
England’s National Institute for Health and Care Excellence (NICE) has recommended that Iqirvo (elafibranor) be covered by the…
Progressive familial intrahepatic cholestasis (PFIC) caused by mutations in the USP53 gene results in a fairly mild form of…